StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SNDXBullishAnalyst Target Updateanalyst
High materiality7/10

Mizuho Reiterates Outperform on Syndax Pharmaceuticals

Nov 3, 2026, 5:26 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The target implies substantial upside, making this a notable bullish analyst view, though it is a reiterated opinion rather than a newly stated catalyst.

AI summary

What happened, with direct paths to the underlying reporting

Mizuho reiterated its Outperform rating on SNDX and gave a $43 target, compared with the posted price of $13.10.

  • Mizuho reiterated Outperform.
  • Target: $43; posted price: $13.10.

Key facts

  1. 01

    Target: $43

  2. 02

    Posted price: $13.1

  3. 03

    Analyst firm: Mizuho Securities

  4. 04

    Analyst: Salim Syed

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.